A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

ClinicalTrials.gov ID: NCT07416604

Public ClinicalTrials.gov record NCT07416604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Emicizumab Prophylaxis in People With Hemophilia A

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.

Study identification

NCT ID: NCT07416604
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 360 participants

Conditions and interventions

Conditions

Hemophilia A

Interventions

NXT007 Combination Product
Emicizumab Drug

Combination Product · Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 27, 2026 (Actual)
Primary completion: Feb 29, 2028 (Estimated)
Completion: Jan 29, 2032 (Estimated)
Last update posted: Oct 6, 2026

2026 – 2032

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
Center for Inherited Blood Disorders	Orange	California	92868	Recruiting
University of Colorado Hemophilia and Thrombosis Center	Aurora	Colorado	80045-7202	Recruiting
University Of Miami Hospital	Miami	Florida	33136	Recruiting
St Joseph's Children's Hospital of Tampa	Tampa	Florida	33607-6307	Recruiting
Innovative Hematology, Inc.	Indianapolis	Indiana	46260	Recruiting
University Of Iowa Hospitals And Clinics	Iowa City	Iowa	52242-1009	Recruiting
University of Michigan - 1500 E Medical Center Dr	Ann Arbor	Michigan	48109-5000	Recruiting
M Health Fairview - Pediatric Specialty Clinic-Discovery	Minneapolis	Minnesota	55454-1404	Recruiting
The University of Texas Health Science Center at San Antonio	San Antonio	Texas	78229	Recruiting
Washington Center for Bleeding Disorders	Seattle	Washington	98101-3932	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07416604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 6, 2026 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07416604 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →